Allievex is a clinical‐stage biotechnology company founded by Pappas Capital that is developing novel therapies for the treatment of rare pediatric neurodegenerative diseases. Allievex’s lead product candidate is tralesinidase alfa, an investigational enzyme replacement therapy using a novel fusion of recombinant human alpha‐N‐acetyglucosaminidase (NAGLU) with a peptide derived from insulin‐like growth factor 2 (IGF2) for the treatment of children with Sanfilippo syndrome type B or mucopolysaccharidosis IIIB (MPS IIIB).